Paliperidone Liconsa (Paliperidone Palmitate)

Paliperidone Palmitate works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors, while also modulating other serotonergic and adrenergic pathways. This combined antagonism reduces dopaminergic over‑activity that underlies psychotic symptoms and helps stabilise mood.

The dosing regimen for Paliperidone Liconsa is determined by the prescribing clinician based on the patient’s clinical status, prior response to oral paliperidone, and any loading‑dose requirements. The prescriber will decide the exact dose and injection schedule.

Limited clinical data are available for Paliperidone Liconsa during pregnancy and lactation. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Paliperidone Liconsa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Paliperidone Liconsa offers a once‑monthly injectable option, which can improve adherence compared with daily oral antipsychotics. Compared with other long‑acting injectables such as risperidone microspheres, it provides a different dosing schedule and may have a distinct side‑effect profile, particularly regarding prolactin elevation and metabolic changes.

Paliperidone Liconsa should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures. Do not freeze the vials, and keep them out of reach of children.

Paliperidone Liconsa is administered by a qualified healthcare professional as an intramuscular injection, typically into the gluteal or deltoid muscle. The injection is given once every four weeks after any required loading doses, and the site should be rotated according to clinical guidelines.

Serious risks include tardive dyskinesia, neuroleptic malignant syndrome, severe hypotension, hyperglycaemia, and seizures. Patients should be monitored for early signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Paliperidone Liconsa is contraindicated in individuals with known hypersensitivity to paliperidone or any excipients in the formulation. Caution is advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome.